SUPPLEMENTAL MATERIALS

Cardiac arrhythmias after COVID-19 vaccination versus non–COVID-19 vaccination: a systematic review and meta-analysis

TABLE OF CONTENTS

Table S1. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 Checklist
Table S2. Detailed description of the search strategy
Table S3. Data collection template: Cardiac arrhythmias in vaccination10
Table S4. Demographics and outcomes of included studies 11
Table S5. Joanna Briggs Institute Checklist for Prevalence Studies
Table S6. Grading of Recommendations, Assessment, Development, and Evaluations 22
Table S7: Results of the sensitivity analyses for the primary meta-analysis. 24
Figure S1. Funnel plot and Egger test for primary meta-analysis of cardiac arrhythmias after vaccination
Figure S2. Incidence of tachyarrhythmia among those receiving COVID-19 and non–COVID-19 vaccines
Figure S3. All-cause mortality among those receiving COVID-19 and non–COVID-19 vaccines
Figure S4. Incidence of cardiac arrhythmias after COVID-19, human papillomavirus, influenza, acellular pertussis, and mixed vaccines
Figure S5. Incidence of cardiac arrhythmias after COVID-19 and influenza vaccines
Figure S6. Incidence of cardiac arrhythmias after COVID-19 and human papillomavirus vaccines

Figure S7. Incidence of cardiac arrhythmias after COVID-19 and acellular pertussis vaccines	32
Figure S8. Incidence of cardiac arrhythmias after COVID-19 and smallpox vaccines	33
Figure S9. Incidence of cardiac arrhythmias among those receiving mRNA COVID-19 and non–mRNA COVID-19 vaccines	34
Figure S10. Incidence of cardiac arrhythmias among those receiving their first, second, and third dose of COVID-19 vaccine	35
Figure S11. Incidence of cardiac arrhythmias after vaccination among adults and children	36

TABLE S1. PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES (PRISMA) 2020 CHECKLIST

Section and	ltem		Location
	#	Checklist item	where item is
			reported
TITLE			
Title	1	Identify the report as a systematic review.	P1-2
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	P3-4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	P5
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	P5
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	P6
Information	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify	P6
sources		studies. Specify the date when each source was last searched or consulted.	
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	P6, Table S2
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers	P6
		screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation	
		tools used in the process.	
Data collection	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report,	P6
process		whether they worked independently, any processes for obtaining or confirming data from study investigators, and if	
		applicable, details of automation tools used in the process.	
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome	P7, Table S3
		domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide	
		which results to collect.	

Section and Topic	ltem #	Checklist item	Location where item is reported
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	P7, Table S3
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	P6-7
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	P7-8
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	P7-8
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	P7-8
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	P7-8
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	P7-8
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta- regression).	P7-8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	P7-8
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	P7-8
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	P7-8

Section and Topic	ltem #	Checklist item	Location where item is reported
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	P8
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	P8
Study characteristics	17	Cite each included study and present its characteristics.	P8 Supplementary P11-19
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Supplementary P20-22
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	P8 Supplementary P11-19
Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Table S6
syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	P8-10 Supplementary P27-36
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	P8-10
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	P8-10
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Table S6
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Table S6
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	P10-13

Section and Topic	ltem #	Checklist item	Location where item is reported
	23b	Discuss any limitations of the evidence included in the review.	P13
	23c	Discuss any limitations of the review processes used.	P13
	23d	Discuss implications of the results for practice, policy, and future research.	P13-14
OTHER INFORMAT	ΓΙΟΝ		
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	P6
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	P6
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	P6
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	P14
Competing interests	26	Declare any competing interests of review authors.	P14
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	P14

PubMed

- #1 Arrhythmias, Cardiac [MeSH Terms]
- #2 (dysrhythmia[Title/Abstract]) OR (arrhythmi*[Title/Abstract]) OR (dysrhythmi*[Title/Abstract]) OR (tachycardia[Title/Abstract]) OR (bradycardia[Title/Abstract] OR (fibrillation[Title/Abstract]) OR (flutter[Title/Abstract]) OR (supraventricular arrhythmia[Title/Abstract]) OR (ventricular tachycardia[Title/Abstract]) OR (ventricular fibrillation[Title/Abstract]) OR (atrial fibrillation[Title/Abstract]) OR (atrioventricular re-entrant tachycardia[Title/Abstract]) OR (atrioventricular nodal re-entrant tachycardia[Title/Abstract]) OR (supraventricular tachycardia[Title/Abstract]) OR (atrioventricular block[Title/Abstract]) OR (AV block[Title/Abstract]) OR (heart block[Title/Abstract])
- #3 #1 OR #2
- #4 vaccines [MeSH Terms]
- #5 vaccine[Title/Abstract])
- #6 #4 OR #5
- #7 #3 AND #6

Embase

#1 Heart arrhythmia/exp

#2 (dysrhythmia OR arrhythmi* OR dysrhythmi* OR tachycardia OR bradycardia OR fibrillation OR flutter OR supraventricular arrhythmia
 OR ventricular arrhythmia OR ventricular tachycardia OR ventricular fibrillation OR atrial fibrillation OR atrial flutter OR atrial tachycardia

OR atrioventricular re-entrant tachycardia OR atrioventricular nodal re-entrant tachycardia OR supraventricular tachycardia OR

atrioventricular block OR AV block OR heart block):ti,ab,kw

- #3 #1 OR #2
- #4 vaccines/exp
- #5 vaccine:ti,ab,kw
- #6 #4 OR #5
- #7 #3 AND #6

Cochrane Database of Systematic Reviews

- #1 MeSH descriptor:[Arrhythmias, Cardiac]explode all trees
- #2 (dysrhythmia OR arrhythmi* OR dysrhythmi* OR tachycardia OR bradycardia OR fibrillation OR flutter OR supraventricular arrhythmia
 OR ventricular arrhythmia OR ventricular tachycardia OR ventricular fibrillation OR atrial fibrillation OR atrial flutter OR atrial tachycardia
 OR atrioventricular re-entrant tachycardia OR atrioventricular nodal re-entrant tachycardia OR supraventricular tachycardia OR atrioventricular block OR AV block OR heart block):ti,ab,kw
- #3 #1 OR #2
- #4 MeSH descriptor:[vaccines]explode all trees
- #5 vaccine:ti,ab,kw
- #6 #4 OR #5
- #7 #3 AND #6

Scopus

- #1 TITLE-ABS-KEY("arrhythmia" OR "dysrhythmia" OR "arrhythmi*" OR "dysrhythmi*" OR "tachycardia" OR "bradycardia" OR "fibrillation"
 OR "flutter" OR "supraventricular arrhythmia" OR "ventricular arrhythmia" OR "ventricular tachycardia" OR "ventricular fibrillation" OR
 "atrial fibrillation" OR "atrial flutter" OR "atrial tachycardia" OR "atrioventricular re-entrant tachycardia" OR "atrioventricular nodal re entrant tachycardia" OR "supraventricular tachycardia" OR "atrioventricular block" OR "AV block" OR "heart block")
- #2 TITLE-ABS-KEY(vaccines OR vaccine)
- #3 #1 AND #2

TABLE S3. DATA COLLECTION TEMPLATE: CARDIAC ARRHYTHMIAS IN VACCINATION

Study characteristics: Study authors, year published, vaccine characteristics, No. of doses, characteristics of those receiving vaccination, definitions of arrhythmia, outcomes reported, all mortality, follow-up duration.

Baseline demographics: Age, number or proportion of males, comorbidities

Vaccine characteristics: COVID-19 vaccine, HPV, acellular pertussis, influenza, smallpox, epidemic cerebrospinal meningitis and pneumococcal conjugate vaccine

Outcomes: arrhythmia, irregular heartbeat, atrial fibrillation, tachycardia, bradycardia

TABLE S4. DEMOGRAPHICS AND OUTCOMES OF INCLUDED STUDIES

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
Myers 2017	USA	Menveo	8200000	Median: 12 y	Self-report (VAERS	Postural orthostatic	1	-
				Male 47%	and MedDRA)	tachycardia syndrome: 1		
Kaasenbrood 2016	Netherlands	Influenza	9450	64.1±16.5 y	ECG	Atrial fibrillation: 37	-	-
				5075 males				
Sniadack 2008	USA	Smallpox	37901	Median: 48 y	Self-report (VAERS)	Arrhythmias: 7	2	5–12 mo
				Male 36%		Palpitations: 89		
Haber 2016	USA	Pneumococcal	16000000	≥19 y	Self-report (VAERS)	Atrial fibrillation: 4	≥65 y: 14	-
		conjugate						
		vaccine (PCV13)						
Arana 2017	USA	HPV	80138237	Children and	Clinically confirmed	Postural orthostatic	-	-
			4vHP	adults	(diagnostic criteria	tachycardia syndrome:		
			715000 2vHPV		for POTS)	4vHP: 13		
			3905585			2vHPV: 0		
			9vHPV			9vHPV: 0		
Ankrah 2013	Netherlands	A(H1N1) 2009	5870	Mean: 34 y	Self-report	Tachycardia: 6	-	1 wk
				2111 males	(MedDRA)			
Aguirre-Boza 2021	Chile	Acellular	4951556	Infants <2 y	Self-report	Bradycardia: 5	-	-
		pertussis			(MedDRA)			
Arana 2018	USA	4vHPV	60461220	Children and	Clinically confirmed	Postural orthostatic	92	-
				adults	(confirmed cases	tachycardia syndrome: 11		
					following clinical			
					review of reports)			
Choe 2011	Korea	Trivalent	75000000	Children and	Self-report (KVICP)	Bradycardia: 1	-	-
		inactivated		adults				
		influenza						

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
Montano 2021	Germany	Influenza	438100000	-	Self-report (VAERS	Arrhythmia: 619	-	-
					and EudraVigilance)			-
		COVID-19:	34643783	Age		Arrhythmia: 97778	-	
		AstraZeneca or	AstraZeneca	18-64 y:		AstraZeneca: 20614		
		Pfizer or	32233117	335766004		Janssen: 5574		
		Moderna or	Janssen	≥65 y: 116250604		Moderna: 23869		
		Janssen	105518547			Pfizer: 47721		
			Moderna	226008303.5				
			279620827	males				
			Pfizer					
Phillips 2020	Australia	4vHPV	900000	Children and adult	Self-report (VAERS	Postural orthostatic	-	-
					and MedDRA)	tachycardia syndrome: 7		
Petousis-Harris	New Zealand	Tdap	793	Mean: 32 y	-	Tachycardia: 1		4 wk
2016				<20 y: 12				
				20-24 y: 65				
				25-29 y: 180				
				30-34 y: 307				
				35-39 y: 180				
				≥40 γ: 49				
				Women in wk 28–				
				38 of pregnancy				
Ab Rahman 2022	Malaysia	COVID-19:	15387585		ICD-10		8	-
		BNT162b2						
		COVID-19:	17030243	-				
		CoronaVac						
Petousis-Harris 2016 Ab Rahman 2022	Malaysia	COVID-19: BNT162b2 COVID-19: CoronaVac	793 15387585 17030243	 Wean: 32 y <20 y: 12 20-24 y: 65 25-29 y: 180 30-34 y: 307 35-39 y: 180 ≥40 y: 49 Women in wk 28– 38 of pregnancy 	- ICD-10	Tacnycardia: 1	8	4 WK -

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
		COVID-19:	2744507	Age		Arrhythmias: 1375		
		ChAdOx1		12-17 y: 17356		(834 BNT162b2; 485		
		COVID-19:	39174	18-39 y: 10247762		CoronaVac; 53 ChAdOx1; 3		
		Others		40-59 y: 6263483		Others)		
				60+ y: 3278612				
				9919733 males				
Kaur 2021	India	COVID-19:	1 st dose: 804	Mean (±SD): 38.44	Self-report	Tachycardia:1 st dose: 4	-	15 mo
		ChAdOx1	2 nd dose: 802	(±11.47)	(MedDRA)	2 nd dose: 0		
				573 males				
Kant 2022	Netherlands	COVID-19:	14338	Age	Self-report	Arrhythmia: 14	-	6 mo
		AstraZeneca		12-20 y: 369	(MedDRA)	(6 AstraZeneca; 7 Pfizer;		
				21-65 y: 17527		1 Moderna; 0 Janssen)		
		COVID-19:	23115	66-80 y: 6757		Tachycardia: 14		
		Pfizer		>80 y: 2901		(8 AstraZeneca; 1 Pfizer;		
		COVID-19:	5867			4 Moderna; 1 Janssen)		
		Moderna		10622 males		Atrial fibrillation: 11		
		COVID-19:	2458			(4 AstraZeneca; 6 Pfizer;		
		Janssen				1 Moderna; 0 Janssen)		
						Heart rate irregular: 10		
						(2 AstraZeneca; 6 Pfizer;		
						1 Moderna; 1 Janssen)		
						Atrioventricular block		
						complete: 1		
						(0 AstraZeneca; 1 Pfizer;		
						0 Moderna; 0 Janssen)		

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
						Palpitation: 203		
						(106 AstraZeneca;		
						48 Pfizer; 32 Moderna;		
						17 Janssen)		
Mansanguan 2022	Thailand	COVID-19:	301	Age	ECG	Sinus rhythm with sinus	-	14 d
		BNT162b2		Mean (±SD): 15		arrhythmia: 22		
				(±1.6)		Sinus tachycardia: 20		
				13-15 y: 207		Sinus bradycardia: 4		
				16-18 y: 94		Premature atrial		
						contraction: 3		
				202 males		Premature ventricular		
				(adolescents)		contraction: 2		
						Junctional escape rhythm:		
						1		
						Ectopic atrial rhythm: 1		
El-Shitany 2022	Egypt	COVID-19:	2nd dose: 442	Age	Self-report (a	Arrhythmia: 2nd dose: 25	-	-
		Pfizer	3rd dose: 442	< 60 y: 367	Google form-based	3rd dose: 30		
				≥ 60 y: 75	questionnaire, the			
					scientific terms for			
				123 males	the symptoms were			
					written and			
					explained in the			
					public language)			
Farhat 2022	Saudi Arabia	COVID-19:	1st dose: 772	Age	Self-report (a	Fast or irregular heartbeat:	-	-
		Pfizer	2nd dose: 816	12-17 y: 33	Google form-based	1st dose: 95		
			3rd dose: 142	18-29 y: 239	questionnaire, the	2nd dose: 85		

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
		COVID-19:	1st dose: 217	30-49 y: 424	scientific terms for	3rd dose: 1		
		Oxford	2nd dose: 162	50-65 y: 301	the symptoms were			
			3rd dose: 2	>65 y: 21	written and			
					explained in the			
				390 males	public language)			
Lai 2022	Hong Kong,	COVID-19:	1st dose:	12-18 у	ICD-9	Arrhythmia:	-	-
	China	BNT162b2	138141			1st dose: 7		
			2nd dose:	1st dose: 69572		2nd dose: 12		
			119664	males				
				2nd dose: 61168				
				males				
Almufty 2021	Iraq	COVID-19:	608	Age	Self-report (a	Tachycardia:2	-	-
		AstraZeneca		18-30 y: 420	standardized	(1 AstraZeneca; 1 Pfizer)		
		COVID-19:	296	31-49 y: 424	questionnaire			
		Pfizer		50-69 y: 150	platform was used			
		COVID-19:	108	≥70 y: 18	to collect			
		Sinopharm			information)			
				609 males				
Patone 2022	UK	COVID-19:	1st dose:	1st dose: Age	Clinically confirmed	Arrhythmia:	-	-
		ChAdOx1	20615911	16-29 y: 5767025		1st dose: 42740		
			2nd dose:	30-39 y: 5910138		2nd dose: 44014		
			19754224	40+ y: 26938328				
		COVID-19:	1st dose:	2nd dose: Age				
		BNt162b2	16993389	16-29 y: 2258383				
			2nd dose:	30-39 y: 4130788				
			11972733	40+ y: 25706577				

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
		COVID-19:	1st dose:	1st dose:				
		mRNA-1273	1006191	12883163 males				
			2nd dose:	2nd dose:				
			368791	10905154 males				
Ortiz-Prado 2022	Ecuador	COVID-19:	1st dose: 2069	Age	Self-report (online	Tachycardia: 257	-	-
		Pfizer	2nd dose:2069	10-20 y: 204	questionnaire)	(106 Pfizer;		
				21-30 y: 1553		101 AstraZeneca;		
				31-40 y: 1895		50 Sinovac)		
		COVID-19:	1st dose: 2553	41-50 y: 1471				
		AstraZeneca	2nd dose:2553	51-60 y: 997				
				61-70 y: 428				
				71-80 y: 82				
		COVID-19:	1st dose: 2032	81-90 y: 19				
		Sinovac	2nd dose:2032	91-100 y: 5				
				2631 males				
Abdel-Qader 2022	Jordan	COVID-19:	610591	Mean: 36.5 y	Self-report	Tachycardia: 1st dose:	11	8 mo
		BNT162b2		_	(telephone survey)	2430		
		COVID-19:	279606	622844 males		2nd dose: 1538		
		BBIBP-CorV		_				
		COVID-19:	140843					
		ChAdOx1						
		COVID-19:	1390					
		Sputnik V						
Basavaraja 2021	India	COVID-19:	9292		Self-report	Tachycardia: 1st dose: 2	-	90 d
		COVISHIELD			(MedDRA)	2nd dose: 0		

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
		COVID-19:	2364	≥18 y				
		COVAXIN						
Cari 2021	Italy	COVID-19:	48071531	≥18 y	EudraVigilance	Tachycardia:2	-	-
		ChAdOx1			European database	(2918 ChAdOx1;		
		COVID-19:	5891506			144 Ad26.COV2.S;		
		Ad26.COV2.S				4729 BNT162b2)		
		COVID-19:	213021122					
		BNT162b2						
Decker 2021	USA	Smallpox:	897227	≥17 y	ICD-9 and ICD-10	Arrhythmia: 131	1	-
		ACAM2000				(10 ACAM2000;		
						121 Dryvax)		
		Smallpox:	450000			Atrial Fibrillation: 1	-	_
		Dryvax				(1 ACAM2000; 0 Dryvax)		
						Supraventricular		
						Tachycardia: 3		
						(3 ACAM2000; 0 Dryvax)		
						Tachycardia Paroxysmal: 1		
						(1 ACAM2000; 0 Dryvax)		
						Palpitation: 146		
						(28 ACAM2000;		
						118 Dryvax)		
Tavakoli 2022	Iran	COVID-19:	1315	Mean: 14.5 y	Self-report	Arrhythmia: 18	-	-
		Soberana			(telephone survey)	(4 Soberana;		
		COVID-19:	9727	5374 males		14 Sinopharm)		
		Sinopharm						
						Palpitation: 49		

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
						(7 Soberana; 42		
						Sinopharm)		
Wong 2022	Hong Kong,	COVID-19:	1st dose:	Mean: 49.8 y	ICD-9-CM	Arrhythmia: 458	1st dose:	-
	China	BNT162b2	1308820			(224 BNT162b2;	42	
			2nd dose:	1024086 males		14 CoronaVac)	2nd dose:	
			1116677				34	_
		COVID-19:	1st dose:				1st dose:	
		CoronaVac	955859				53	
			2nd dose:				2nd dose:	
			821560				33	
Abu-Hammad 2021	Jordan	COVID-19:	89	Mean: 35.0 y	Self-report (online	Palpitations: 1	-	-
		SinoPharm			questionnaire)	(0 SinoPharm; 0 Pfizer		
		COVID-19:	141	120 males		BioNTech; 1 AstraZeneca		
		Pfizer BioNTech		_		Vaxezevira)		
		COVID-19:	179					
		AstraZeneca						
		Vaxezevira						
Alghamdi 2021	Saudi Arabia	COVID-19:	2601	Age	Self-report (online	Palpitations: 462	-	-
		BNT162b2		<20 y: 671	questionnaire)	(193 BNT162b2;		
				20-30 y: 1965		269 ChAdOx1)		
				31-40 y: 671				
		COVID-19:	1569	41-50 y: 582				
		ChAdOx1		51-60 y: 227				
				>60 y: 54				
				1296 males				

				Characteristics of				
		Vaccine	Number of	those receiving	Definitions of		All-cause	Follow-up
Study	Country	characteristics	doses	vaccination	arrhythmia	Outcomes reported	mortality	duration
Alghamdi 2022	Saudi Arabia	COVID-19:	526	Mean: 39.7 y	Self-report (online	Palpitations: 59	-	-
		AstraZeneca			questionnaire)			
				244 males				
Chen 2022	Taiwan,	COVID-19:	5374	Age	Self-report (VAERS)	Palpitations: 78	-	3 mo
	China	mRNA1273		<40 y: 3011		(46 mRNA1273;		
		COVID-19:	1182	<65 y: 3751		24 BNT162b2; 8 MVC-		
		BNT162b2		≥65 y: 620		COV1901)		
		COVID-19:	826	-				
		MVC-COV1901		2461 males				
Engler 2015	USA	Smallpox	1st dose: 1081	Mean: 25.3 y	Self-report	Palpitations: 12	-	58 mo
					(telephone and/or			
		Influenza	1st dose: 189	1058 males	electronic mail)	Palpitations: 2		
Halder 2022	Australia	COVID-19:	57,842	Mean: 40.6 y	Self-report	Palpitations: 8	-	-
		BNT162b2			(electronic medical			
				-	records)			
Vanijcharoenkarn	USA	SARSCoV-2	1st dose:	-	Self-report	Palpitations: 16	-	-
2021		mRNA Vaccines	20,657		(occupational health			
					records)			
Wang 2021	China	COVID-19	4458	-	Self-report	Palpitations: 4	-	-
		vaccine:			(recorded in			
		Aikewei			Children's Hospital			
					of Fudan University)			

TABLE S5. JOANNA BRIGGS INSTITUTE CHECKLIST FOR PREVALENCE STUDIES

Study	1	2	3	4	5	6	7	8	9	Overall
Myers 2017	\checkmark					?			?	7
Kaasenbrood 2016	\checkmark								\checkmark	9
Sniadack 2008	\checkmark			?		×		\checkmark	\checkmark	7
Haber 2016	\checkmark					×	×	\checkmark	\checkmark	7
Arana 2017	\checkmark					\checkmark	\checkmark	\checkmark	\checkmark	9
Ankrah 2013	\checkmark					×	×			7
Aguirre-Boza 2021	\checkmark					×	×	\checkmark	\checkmark	7
Arana 2018	\checkmark					\checkmark		\checkmark	\checkmark	9
Choe 2011	\checkmark	?		?		×	?			5
Montano 2021	\checkmark					×	×			7
Phillips 2020	\checkmark					×	×			7
Petousis-Harris 2016	\checkmark		×			?	?			6
Ab Rahman 2022	\checkmark	?								8
Kaur 2021	\checkmark					?	?	\checkmark	\checkmark	7
Kant 2022	\checkmark					×		\checkmark	\checkmark	8
Mansanguan 2022	\checkmark		×			\checkmark		\checkmark	\checkmark	8
El-Shitany 2022	×		×			×				6
Farhat 2022	\checkmark					×	?			7
Lai 2022	\checkmark									9
Almufty 2021	\checkmark	?				×		\checkmark	\checkmark	7
Patone 2022	\checkmark					\checkmark		\checkmark	\checkmark	9
Ortiz-Prado 2022	\checkmark					×	\checkmark			8
Abdel-Qader 2022	\checkmark					×		\checkmark	\checkmark	8

Basavaraja 2021	\checkmark		\checkmark	?		×			\checkmark	7
Cari 2021	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	?	?	\checkmark	\checkmark	7
Decker 2021	\checkmark	\checkmark	\checkmark	?	\checkmark			?	\checkmark	7
Tavakoli 2022			\checkmark	\checkmark	\checkmark	×			\checkmark	8
Wong 2022	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark				\checkmark	9
Abu-Hammad 2021			×	\checkmark	\checkmark	×			\checkmark	7
Alghamdi 2021		?	\checkmark	\checkmark		×			\checkmark	7
Alghamdi 2022	×	\checkmark	×	\checkmark	\checkmark	×	?		\checkmark	5
Chen 2022	×	\checkmark	\checkmark	\checkmark	\checkmark	×			\checkmark	7
Engler 2015	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	×			\checkmark	8
Halder 2022			\checkmark	\checkmark	\checkmark	×	×	?	\checkmark	6
Vanijcharoenkarn 2021			\checkmark	\checkmark		×		?	\checkmark	7
Wang 2021			\checkmark			×		?		7

 $\sqrt{1}$: Yes, \times : no, ?: unclear.

Domains:

- 1: Was the sample frame appropriate to address the target population?
- 2: Were study participants sampled in an appropriate way?
- 3: Was the sample size adequate?
- 4: Were the study subjects and the setting described in detail
- 5: Was the data analysis conducted with sufficient coverage of the identified sample?
- 6: Were valid methods used for the identification of the condition?
- 7: Was the condition measured in a standard, reliable way for all participants?
- 8: Was there appropriate statistical analysis?
- 9: Was the response rate adequate, and if not, was the low response rate managed appropriately?

TABLE S6. GRADING OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT, AND EVALUATIONS

							Effect			
	Certainty assess	ment	T	I	I	T	Effect	1	Certainty	Importance
Number		Risk for				Other	Number of	Rate		
of studies	Study design	bias	Inconsistency	Indirectness	Imprecision	considerations	individuals	(95% CI)		
Incidence of	f cardiac arrhythm	nias (assesse								
36	Observational	Not	Serious ^a	Not serious	Not serious	None	1528459662	15014.69	$\oplus \oplus \oplus \bigcirc$	CRITICAL
	studies	serious						per million	Moderate	
								(3958.84-		
								26,070.55)		
Incidence o	f cardiac arrhythm	nias in COVII	D-19 vaccines (asse	ssed with: per mil	lion vaccines)					
23	Observational	Not	Serious ^a	Not serious	Serious ^b	None	830585553	24420.82	$\oplus \oplus \bigcirc \bigcirc$	CRITICAL
	studies	serious						per million	Low	
								(6284.27-		
								42,557.37)		
Incidence o	f cardiac arrhythm	nias in non-C	OVID-19 vaccines (assessed with: pe	r million vaccine	s)				
14	Observational	Not	Not serious ^c	Not serious	Not serious	None	697874109	867.56 per	$\oplus \oplus \oplus \oplus$	CRITICAL
	studies	serious						million	High	
								(0.00-		
								1867.84)		
Mortality (a	ssessed with: per	million vaco	ines)							
8	Observational	Not	Not serious	Not serious	Not serious ^d	None	126033203	8.15 per	$\oplus \oplus \oplus \oplus$	CRITICAL
	studies	serious						million	High	
								(0.00-		
								18.40)		
1	1	1	1			1				

Explanations

- ^a Point estimates were sparsely distributed, and confidence intervals overlapped only occasionally.
- ^b Compared with the combined estimation, the difference in confidence intervals is very large.
- ^c Apart from one study, most of the point estimates were closely clustered, and the confidence intervals overlapped most of the time. Thus, we did not rate down for inconsistency.
- ^d Compared with the combined estimation, the difference in confidence intervals is not very large. Thus, we did not rate down for imprecision.

TABLE S7: RESULTS OF THE SENSITIVITY ANALYSES FOR THE PRIMARY META-ANALYSIS.

Sensitivity analysis	Pooled estimate	95% CI
Excluding studies with high risk for bias	277.8 arrhythmia cases per million vaccine	150.2–513.7
	doses	



FIGURE S1. FUNNEL PLOT AND EGGER TEST FOR PRIMARY META-ANALYSIS OF CARDIAC ARRHYTHMIAS AFTER VACCINATION

FIGURE S2. INCIDENCE OF TACHYARRHYTHMIA AMONG THOSE RECEIVING COVID-19 AND NON-COVID-19 VACCINES

Study	Events	Total		Cases pe	r million vaccine doses(95%Cl)
Vaccine.type = Non-CO	VID-19 va	ccines	i i		
Myers,2017	1	8200000		0.1	[0.0; 0.7]
Arana,2017	13	84758822	0	0.2	[0.1; 0.3]
Ankrah,2013	6	5870		1022.1	[375.2; 2223.4]
Arana,2018	11	60461220		0.2	[0.1; 0.3]
Phillips,2020	7	9000000	<u>i</u>	0.8	[0.3; 1.6]
Petousis-Harris,2016	1	793	+	1261.0	[31.9; 7005.8]
Kaasenbrood,2016	37	9450	•	3915.3	[2758.2; 5392.8]
Sniadack,2008	89	37901	•	2348.2	[1886.2; 2888.9]
Haber,2016	5	16000000		0.3	[0.1; 0.7]
Decker,2021	151	1347227	0	112.1	[94.9; 131.5]
Engler,2015	14	1270	(<u></u>	11023.6	[6039.5; 18426.7]
Random effects model	335	179822553		25.8	[4.5; 149.4]
Heterogeneity: $I^2 = 100\%$, τ^2	= 20.3363,	p < 0.01			
Vaccine.type = COVID-1	9 vaccine	S			
Kaur,2021	4	1606	+	2490.7	[679.0; 6364.7]
Kant,2022	228	45778		4980.6	[4356.3; 5668.8]
Mansanguan,2022	20	301		66445.2	[41055.6; 100756.0]
Almufty,2021	2	1012	÷	1976.3	[239.4; 7120.6]
Ortiz-Prado,2022	257	13308	(🛨	19311.7	[17041.6; 21795.3]
Abdel-Qader,2022	3968	1032430		3843.4	[3724.9; 3964.6]
Basavaraja,2021	2	7735		258.6	[31.3; 933.7]
Tavakoli,2022	49	11042	2	4437.6	[3284.7; 5862.6]
Chen,2022	78	7382	-	10566.2	[8360.9; 13169.8]
Halder,2022	8	57842	Q	138.3	[59.7; 272.5]
Wang,2021	4	4458		897.3	[244.5; 2295.7]
Vanijcharoenkarn,2021	16	20657		774.6	[442.8; 1257.5]
Alghamdi,2021	462	4170		110791.4	[101420.0; 120711.8]
Alghamdi,2022	59	526	<u> </u>	112167.3	[86491.2; 142294.5]
Abu-Hammad,2021	1	409		2445.0	[61.9; 13546.7]
Random effects model	5158	1208656		4367.5	[1535.2; 12360.8]
Heterogeneity: I^2 = 100%, τ^2	= 4.1194, p	0 < 0.01			
Random effects model	5493	181031209		487.1	[127.3; 1862.2]
Heterogeneity: $l^2 = 100\% \tau^2$	= 17.2182	ס < 0.01	20000 40000 60000 80000 1e+05120000		

Heterogeneity: $l^2 = 100\%$, $\tau^2 = 17.2182$, p < 0.01Test for subgroup differences (random effects): $\chi_1^2 = 24.21$, df = 1 (p < 0.01)

FIGURE S3. ALL-CAUSE MORTALITY AMONG THOSE RECEIVING COVID-19 AND NON-COVID-19 VACCINES



FIGURE S4. INCIDENCE OF CARDIAC ARRHYTHMIAS AFTER COVID-19, HUMAN PAPILLOMAVIRUS, INFLUENZA, ACELLULAR PERTUSSIS, AND

MIXED VACCINES

Vaccine.type = HPV Arana.2017 13 84758922 Arana,2018 11 60461220 Phillips.2020 7 9000000 Random effects model 31 154220042 Heterogeneity: i ² = 85%, i ² = 0.3470, p < 0.01 Vaccine.type = COVID-19 vaccines Ab Rahman.2022 1375 35201509 Kanr.2021 4 1606 Kanr.2022 253 45778		0.2 [0.1; 0.3] 0.2 [0.1; 0.3] 0.8 [0.3; 1.6] 0.3 [0.1; 0.5]
Vaccine.type = HPV Arana.2017 13 84758822 Arana.2018 11 60461220 Phillips.2020 7 9000000 Random effects model 31 154220042 Heterogeneity: I ² = 65%, x ² = 0.3470, p ≤ 0.01 Vaccine.type = COVID=19 vaccines Ab Rahman.2022 1375 35201509 Kaur.2021 4 1666 Kanz.0221 4 1676 Mansanoua.2022 253 45778		0.2 [0.1; 0.3] 0.2 [0.1; 0.3] 0.8 [0.3, 1.6] 0.3 [0.1; 0.5]
Arana 2017 13 84758822 Arana 2018 11 60461220 Philips, 2020 7 9000000 Randow effects model 31 15422042 Heterogeneity: i ² = 85%, c ² = 0.3470, p = 0.01 Vaccines Ab Rahman, 2022 Ab Rahman, 2022 1375 35201509 Kaur, 2021 4 1606 Kaur, 2021 4 1606 Kanan, 2022 253 45778		0.2 [0.1; 0.3] 0.2 [0.1; 0.3] 0.8 [0.3; 1.6] 0.3 [0.1; 0.5]
Arana.2018 11 60461220 Phillips.2020 7 90000000 Random effects model 31 154220042 Heterogeneity: I ² = 85%, x ² = 0.3470, p < 0.01		0.2 [0.1; 0.3] 0.8 [0.3; 1.6] 0.3 [0.1; 0.5]
Phillips, 2020 7 9000000 Random effects model 31 154220042 Heterogeneity: I ² = 85%, c ² = 0.3470, p < 0.01		0.8 [0.3; 1.6] 0.3 [0.1; 0.5]
Random effects model 31 154220042 Heterogeneity: i ² = 85%, i ² = 0.3470, p < 0.01		0.3 [0.1; 0.5]
Heterogeneity: <i>i</i> ² = 85%, <i>i</i> ² = 0.3470, <i>p</i> < 0.01 Vaccine: type = COVID-19 vaccines Ab Rahman,2022 1375 35201509 Kaur,2021 4 1606 Kant,2022 253 45778 Mansanouan,2022 53 301		
Vaccine.type = COVID-19 vaccines Ab Rahman.2022 1375 35201509 Kaur.2021 4 1606 Kant.2022 253 45778 Mansanguan.2022 53 301		
Ab Rahman,2022 1375 35201509 Kaur,2021 4 1606 Kant,2022 253 45778 Mansanouan,2022 53 301	<u>i</u>	
Kaur,2021 4 1606 Kaur,2021 253 45778 Mansanguan.2022 53 301		39.1 [37.0: 41.2]
Kant,2022 253 45778 Mansanguan.2022 53 301		2490.7 [679.0: 6364.7]
Mansanguan.2022 53 301		5526.7 [4868.1: 6249.0]
110100000000000000000000000000000000000		176079 7 [134766 1: 223902 6]
Montano 2021 07778 452016274		216.3 [215.0: 217.7]
El=Shitany 2022 55 884		62217.2 [47210.8: 80217.5]
Lai 2022 10 257805		73.7 [44.4: 115.1]
Almufty 2021 2 1012		1076.2 [220.4: 7120.6]
Alliuty,2021 2 1012 Detens 2022 96754 70711220		1000 [200.4, 7120.0]
Ortiz-Brado 2022 257 12209	T an	10211.7 [17041.6: 21705.2]
Offiz=Pfad0,2022 257 13306	· · · · · · · · · · · · · · · · · · ·	19311.7 [17041.6, 21795.3]
ramat,2022 181 2111		00741.4 [74142.4; 98505.0]
Abder-Qader,2022 3968 1032430		3643.4 [3724.9; 3964.6]
Basavaraja,2021 2 7735	¥	208.6 [31.3; 933.7]
Cari,2021 //91 266984159	14 A	29.2 [28.5; 29.8]
таvакоп,2022 6/ 11042	2 ¹⁰	6067.7 [4705.4; 7699.5]
wong,2022 458 4202916	9 <u></u>	109.0 [99.2; 119.4]
Chen,2022 78 7382	<u>i</u>	10566.2 [8360.9; 13169.8]
Halder,2022 8 57842	9 H	138.3 [59.7; 272.5]
Wang,2021 4 4458		897.3 [244.5; 2295.7]
Vanijcharoenkarn,2021 16 20657	P	774.6 [442.8; 1257.5]
Alghamdi,2021 462 4170		110791.4 [101420.0; 120711.8]
Alghamdi,2022 59 526		112167.3 [86491.2; 142294.5]
Abu-Hammad,2021 1 409		2445.0 [61.9; 13546.7]
Random effects model 199645 830585553		2263.4 [875.4; 5839.2]
Heterogeneity: $I^2 = 100\%$, $\tau^2 = 7.2762$, $p < 0.01$		
Vaccine.type = Influenza		
Kaasenbrood,2016 37 9450		3915.3 [2758.2; 5392.8]
Ankrah.2013 6 5870	6	1022.1 [375.2: 2223.4]
Choe 2011 1 75000000	- The second sec	0.0 [0.0: 0.1]
Montano 2021 619 438100000		14 [13; 15]
Engler 2015 2 189	<u>}</u>	10582.0 [1284.1: 37701.1]
Random effects model 665 513115509		53.2 [27.7: 102.3]
Heterogeneity: $I^2 = 100\%$, $\tau^2 = 27.3547$, $p < 0.01$		
Vaccino tuno = Acollular partursis		
Aquirre-Boza 2021 5 4051556	h	10 [03: 24]
Aguine-DoZa,2021 0 4951556 Potousie-Harris 2016 1 702	12 C	1.0 [U.3, 2.4] 1261.0 [21.0-7005.9]
Perdem effects model 6 (050240	7	1201.0 [31.9; /005.8]
Random effects model 6 4952349		21.1 [0.3; 1739.9]
Vaccine type = Smallney		
vaccine.type = Smallpox	÷	2522.0 (2052.4, 2002.2)
SniadaCK,2008 96 37901		2032.9 [2052.1; 3092.3]
Decker;2021 282 1347227		209.3 [185.6; 235.2]
Engler,2015 12 1081	·	11100.8 [5748.8; 19310.6]
Random effects model 390 1386209	•	1747.5 [275.9; 10982.9]
Heterogeneity: $l^2 = 100\%$, $\tau^2 = 2.6099$, $p < 0.01$		
Vaccine.type = Mixed	1	
Myers,2017 1 820000		0.1 [0.0; 0.7]
Haber,2016 5 1600000	•	0.3 [0.1; 0.7]
Random effects model 6 24200000		0.2 [0.1; 0.6]
Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.39$		
Random effects model 200743 1528459662		318.1 [162.4; 622.8]
Heterogeneity: $l^2 = 100\%$, $r^2 = 18.0207$, $n < 0.04$	50000 1e+05 150000 2e+05	

Test for subgroup differences (random effects): $\chi_5^2 = 360.28$, df = 5 (p < 0.01)

FIGURE S5. INCIDENCE OF CARDIAC ARRHYTHMIAS AFTER COVID-19 AND INFLUENZA VACCINES

Study	Events	Total	c	ases per r	million vaccine doses(95%CI)
Vaccine.type = COVID-1	19 vaccine	S	L.		
Ab Rahman,2022	1375	35201509		39.1	[37.0; 41.2]
Kaur,2021	4	1606		2490.7	[679.0; 6364.7]
Kant,2022	253	45778		5526.7	[4868.1; 6249.0]
Mansanguan,2022	53	301	i 1	76079.7	[134766.1; 223902.6]
Montano,2021	97778	452016274		216.3	[215.0; 217.7]
EI-Shitany,2022	55	884	í —	62217.2	[47210.8; 80217.5]
Lai,2022	19	257805	<u>i</u>	73.7	[44.4; 115.1]
Almufty,2021	2	1012		1976.3	[239.4; 7120.6]
Patone,2022	86754	70711239		1226.9	[1218.7; 1235.1]
Ortiz-Prado,2022	257	13308	L 💽	19311.7	[17041.6; 21795.3]
Farhat,2022	181	2111		85741.4	[74142.4; 98505.0]
Abdel-Qader,2022	3968	1032430		3843.4	[3724.9; 3964.6]
Basavaraja,2021	2	7735		258.6	[31.3; 933.7]
Cari,2021	7791	266984159	Q	29.2	[28.5; 29.8]
Tavakoli,2022	67	11042		6067.7	[4705.4; 7699.5]
Wong,2022	458	4202916	0	109.0	[99.2; 119.4]
Chen,2022	78	7382	÷	10566.2	[8360.9; 13169.8]
Halder,2022	8	57842	0	138.3	[59.7; 272.5]
Wang,2021	4	4458		897.3	[244.5; 2295.7]
Vanijcharoenkarn,2021	16	20657		774.6	[442.8; 1257.5]
Alghamdi,2021	462	4170	11	10791.4	[101420.0; 120711.8]
Alghamdi,2022	59	526	1	12167.3	[86491.2; 142294.5]
Abu-Hammad,2021	1	409		2445.0	[61.9; 13546.7]
Random effects model	199645	830585553		2263.4	[875.4; 5839.2]
Heterogeneity: $I^2 = 100\%$, τ^2	² = 7.2762, p	< 0.01	í.		
Vaccine.type = Influenza	a				
Kaasenbrood,2016	37	9450		3915.3	[2758.2; 5392.8]
Ankrah,2013	6	5870	•	1022.1	[375.2; 2223.4]
Choe,2011	1	75000000	.	0.0	[0.0; 0.1]
Montano,2021	619	438100000		1.4	[1.3; 1.5]
Engler,2015	2	189	↓	10582.0	[1284.1; 37701.1]
Random effects model	665	513115509		53.2	[27.7; 102.3]
Heterogeneity: $I^2 = 100\%$, τ^2	² = 27.3547,	p < 0.01	(
Random effects model	200310	1343701062		1167.3	[653.4; 2084.7]
Heterogeneity: $I^2 = 100\%$, τ^2	² = 12.5494,	p < 0.01	50000 1e+05 150000 2e+05		

Test for subgroup differences (random effects): χ_1^2 = 40.62, df = 1 (*p* < 0.01)

FIGURE S6. INCIDENCE OF CARDIAC ARRHYTHMIAS AFTER COVID-19 AND HUMAN PAPILLOMAVIRUS VACCINES

Study	Events	Total				Cases per i	nillion vaccine doses(95%Cl)
Vaccine.type = HPV			i				
Arana 2017	13	84758822	,			0.2	[0.1; 0.3]
Arana,2018	11	60461220	i i			0.2	[0.1; 0.3]
Phillips,2020	7	900000	1			0.8	[0.3; 1.6]
Random effects model	31	154220042	í			0.3	[0.1; 0.5]
Heterogeneity: I^2 = 85%, τ^2	= 0.3470, p	< 0.01					
Vaccine.type = COVID-	19 vaccine	S	í				
Ab Rahman,2022	1375	35201509				39.1	[37.0; 41.2]
Kaur,2021	4	1606	+			2490.7	[679.0; 6364.7]
Kant,2022	253	45778	•		_	5526.7	[4868.1; 6249.0]
Mansanguan,2022	53	301	ţ		+	176079.7	[134766.1; 223902.6]
Montano,2021	97778	452016274				216.3	[215.0; 217.7]
EI-Shitany,2022	55	884	ί			62217.2	[47210.8; 80217.5]
Lai,2022	19	257805	1			73.7	[44.4; 115.1]
Almufty,2021	2	1012	+-			1976.3	[239.4; 7120.6]
Patone,2022	86754	70711239				1226.9	[1218.7; 1235.1]
Ortiz-Prado,2022	257	13308	•			19311.7	[17041.6; 21795.3]
Farhat,2022	181	2111	!			85741.4	[74142.4; 98505.0]
Abdel-Qader,2022	3968	1032430	1 B			3843.4	[3724.9; 3964.6]
Basavaraja,2021	2	7735	•			258.6	[31.3; 933.7]
Cari,2021	7791	266984159	1			29.2	[28.5; 29.8]
Tavakoli,2022	67	11042	+			6067.7	[4705.4; 7699.5]
Wong,2022	458	4202916				109.0	[99.2; 119.4]
Chen,2022	78	7382	+			10566.2	[8360.9; 13169.8]
Halder,2022	8	57842				138.3	[59.7; 272.5]
Wang,2021	4	4458	•			897.3	[244.5; 2295.7]
Vanijcharoenkarn,2021	16	20657	•			774.6	[442.8; 1257.5]
Alghamdi,2021	462	4170	!			110791.	[101420.0; 120711.8]
Alghamdi,2022	59	526	į.			4112167.3	[86491.2; 142294.5]
Abu-Hammad,2021	1	409	+			2445.0	[61.9; 13546.7]
Random effects model	199645	830585553	į			2263.4	[875.4; 5839.2]
Heterogeneity: $I^2 = 100\%$, τ	² = 7.2762, µ	0 < 0.01	ŗ				
Random effects model	199676	984805595	ļ			787.8	[425.2; 1459.2]
	2		, 0	50000 1e+05 1500	00 2e+05 250	000	
Heterogeneity: I^{2} = 100%, τ	~ = 14.8055,	p < 0.01	v				

Test for subgroup differences (random effects): $\chi_1^2 = 223.53$, df = 1 (p < 0.01)

FIGURE S7. INCIDENCE OF CARDIAC ARRHYTHMIAS AFTER COVID-19 AND ACELLULAR PERTUSSIS VACCINES

Study	Events	Total			Cases pe	r million vaccine doses(
Vaccine.type = COVID-1	19 vaccine	S	ι			
Ab Rahman,2022	1375	35201509	•		39.1	[37.0; 41.2]
Kaur,2021	4	1606	+-		2490.7	[679.0; 6364.7]
Kant,2022	253	45778			5526.7	[4868.1; 6249.0]
Mansanguan,2022	53	301			176079.7	[134766.1; 223902.6]
Montano,2021	97778	452016274			216.3	[215.0; 217.7]
EI-Shitany,2022	55	884			62217.2	[47210.8; 80217.5]
Lai,2022	19	257805	÷.		73.7	[44.4; 115.1]
Almufty,2021	2	1012	+		1976.3	[239.4; 7120.6]
Patone,2022	86754	70711239	÷.		1226.9	[1218.7; 1235.1]
Ortiz-Prado,2022	257	13308	ί. 🔸		19311.7	[17041.6; 21795.3]
Farhat,2022	181	2111	i		85741.4	[74142.4; 98505.0]
Abdel-Qader,2022	3968	1032430			3843.4	[3724.9; 3964.6]
Basavaraja,2021	2	7735			258.6	[31.3; 933.7]
Cari,2021	7791	266984159	•		29.2	[28.5; 29.8]
Tavakoli,2022	67	11042	+		6067.7	[4705.4; 7699.5]
Wong,2022	458	4202916			109.0	[99.2; 119.4]
Chen,2022	78	7382	! +		10566.2	[8360.9; 13169.8]
Halder,2022	8	57842			138.3	[59.7; 272.5]
Wang,2021	4	4458	•		897.3	[244.5; 2295.7]
Vanijcharoenkarn,2021	16	20657	•		774.6	[442.8; 1257.5]
Alghamdi,2021	462	4170	i		110791.4	[101420.0; 120711.8]
Alghamdi,2022	59	526	i.		112167.3	[86491.2; 142294.5]
Abu-Hammad,2021	1	409	+		2445.0	[61.9; 13546.7]
Random effects model	199645	830585553	i,		2263.4	[875.4; 5839.2]
Heterogeneity: $I^2 = 100\%$, τ^2	² = 7.2762, p	0 < 0.01	í			
Vaccine.type = Acellula	r pertussis	5	į			
Aguirre-Boza,2021	5	4951556			1.0	[0.3; 2.4]
Petousis-Harris,2016	1	793	+-		1261.0	[31.9; 7005.8]
Random effects model	6	4952349	i.		21.1	[0.3; 1739.9]
Heterogeneity: I^2 = 98%, τ^2	= 10.4220, p	0 < 0.01	i.			
Random effects model	199651	835537902	E.		1590.7	[911.1; 2775.6]
	0.0005		–	50000 1e+05 150000 2e+05	250000	
Heterogeneity: $I^{-} = 100\%$, τ^{+}	= 9.0293, p	0 < 0.01	-			

s(95%Cl)

Test for subgroup differences (random effects): $\chi_1^2 = 4.12$, df = 1 (p = 0.04)

FIGURE S8. INCIDENCE OF CARDIAC ARRHYTHMIAS AFTER COVID-19 AND SMALLPOX VACCINES

Study	Events	Total		Cases per million vaccine doses(95%CI
Vaccine.type = COVID-1	9 vaccine	S	ļ.	
Ab Rahman,2022	1375	35201509	<u>i</u>	39.1 [37.0; 41.2]
Kaur,2021	4	1606	-	2490.7 [679.0; 6364.7]
Kant,2022	253	45778		5526.7 [4868.1; 6249.0]
Mansanguan,2022	53	301	· · · · · · · · · · · · · · · · · · ·	176079.7 [134766.1; 223902.6]
Montano,2021	97778	452016274	<u> </u>	216.3 [215.0; 217.7]
EI-Shitany,2022	55	884	· · · · · · · · · · · · · · · · · · ·	62217.2 [47210.8; 80217.5]
Lai,2022	19	257805	Ċ.	73.7 [44.4; 115.1]
Almufty,2021	2	1012	E	1976.3 [239.4; 7120.6]
Patone,2022	86754	70711239		1226.9 [1218.7; 1235.1]
Ortiz-Prado,2022	257	13308	• •	19311.7 [17041.6; 21795.3]
Farhat,2022	181	2111	ά —	85741.4 [74142.4; 98505.0]
Abdel-Qader,2022	3968	1032430		3843.4 [3724.9; 3964.6]
Basavaraja,2021	2	7735		258.6 [31.3; 933.7]
Cari,2021	7791	266984159		29.2 [28.5; 29.8]
Tavakoli,2022	67	11042	•	6067.7 [4705.4; 7699.5]
Wong,2022	458	4202916	ġ.	109.0 [99.2; 119.4]
Chen,2022	78	7382	+	10566.2 [8360.9; 13169.8]
Halder,2022	8	57842	<u> </u>	138.3 [59.7; 272.5]
Wang,2021	4	4458		897.3 [244.5; 2295.7]
Vanijcharoenkarn,2021	16	20657		774.6 [442.8; 1257.5]
Alghamdi,2021	462	4170	i 🗕	110791. [101420.0; 120711.8]
Alghamdi,2022	59	526	i	4112167.3 [86491.2; 142294.5]
Abu-Hammad,2021	1	409	+	2445.0 [61.9; 13546.7]
Random effects model	199645	830585553	Ę	2263.4 [875.4; 5839.2]
Heterogeneity: $I^2 = 100\%$, τ^2	= 7.2762, p	0 < 0.01		
Vaccine.type = Smallpox	c		ç	
Sniadack,2008	96	37901		2532.9 [2052.1; 3092.3]
Decker,2021	282	1347227	0	209.3 [185.6; 235.2]
Engler,2015	12	1081	ú 🛻	11100.8 [5748.8; 19310.6]
Random effects model	390	1386209		1747.5 [275.9; 10982.9]
Heterogeneity: $I^2 = 100\%$, τ^2	= 2.6099, p	0 < 0.01		
Random effects model	200035	831971762		2201.5 [1210.8; 3999.8]
Heterogeneity: I^2 = 100%, τ^2	= 6.7441, p	o < 0.01	50000 1e+05 150000	2e+05

Test for subgroup differences (random effects): $\chi_1^2 = 0.06$, df = 1 (p = 0.81)

FIGURE S9. INCIDENCE OF CARDIAC ARRHYTHMIAS AMONG THOSE RECEIVING mRNA COVID-19 AND NON-mRNA COVID-19 VACCINES

Study	Events	Total			Cases per million	n vaccine doses(95%CI)	
Vaccine.type = mRNA C	OVID-19 v	/accines	į.				
Ab Rahman,2022	834	15387585	÷		54.2	[50.6; 58.0]	
Kant,2022	108	28982	•		3726.5	[3057.9; 4497.4]	
Mansanguan,2022	53	301	i i		176079.7	[134766.1; 223902.6]	
Montano,2021	71590	385139374	1		185.9	[184.5; 187.2]	
El-Shitany,2022	55	884	i i		62217.2	[47210.8; 80217.5]	
Lai,2022	19	257805			73.7	[44.4; 115.1]	
Almufty,2021	1	296	+		3378.4	[85.5; 18678.4]	
Patone,2022	39510	30341104			1302.2	[1289.4; 1315.1]	
Farhat,2022	136	1730	1		78612.7	[66364.7; 92311.6]	
Abdel-Qader,2022	1572	610591			2574.6	[2449.0; 2704.9]	
Cari,2021	4729	213021122	1		22.2	[21.6; 22.8]	
Wong,2022	224	2425497	1		92.4	[80.7; 105.3]	
Chen,2022	70	6556	+		10677.2	[8332.6; 13471.0]	
Halder,2022	8	57842	•		138.3	[59.7; 272.5]	
Vanijcharoenkarn,2021	16	20657	•		774.6	[442.8; 1257.5]	
Alghamdi,2021	193	2601			74202.2	[64421.0; 84954.3]	
Ortiz-Prado,2022	101	5106	j 🔤		19780.7	[16139.8; 23984.0]	
Abu-Hammad,2021	0	141	-		0.0	[0.0; 25823.0]	
Random effects model	119219	647308174	Į.		1758.3	[875.6; 3527.7]	
Heterogeneity: $I^2 = 100\%$, τ^2	^e = 8.1018, p	0 < 0.01) C				
Vaccine.type = Non-mR)–19 vaccines	÷.				
Ab Rahman,2022	538	19774750			27.2	[25.0; 29.6]	
Kaur,2021	4	1606	+		2490.7	[679.0; 6364.7]	
Kant,2022	145	16796	+		8633.0	[7289.8; 10150.3]	
Montano,2021	26188	66876900			391.6	[386.9; 396.4]	
Almufty,2021	1	716	+		1396.6	[35.4; 7756.8]	
Patone,2022	47244	40370135	1.0		1170.3	[1159.7; 1180.9]	
Farhat,2022	45	381	÷		118110.2	[87468.4; 154834.7]	
Abdel-Qader,2022	2396	421839			5679.9	[5455.3; 5911.3]	
Basavaraja,2021	2	7735	•		258.6	[31.3; 933.7]	
Cari,2021	3062	53963037	1.		56.7	[54.8; 58.8]	
Tavakoli,2022	67	11042	· •		6067.7	[4705.4; 7699.5]	
Wong,2022	234	1777419			131.7	[115.3; 149.6]	
Chen,2022	8	826			9685.2	[4190.4; 18994.2]	
Alghamdi,2021	269	1569	2		171446.8	[153107.1; 191024.7]	
Alghamdi,2022	59	526			112167.3	[86491.2; 142294.5]	
Abu-Hammad,2021	1	268	+		3731.3	[94.5; 20613.3]	
Wang,2021	4	4458	•		897.3	[244.5; 2295.7]	
Ortiz-Prado,2022	156	8202	(📼		19019.8	[16174.5; 22213.5]	
Random effects model	80423	183238205	i i		2528.1	[960.9; 6634.6]	
Heterogeneity: $I^2 = 100\%$, τ^2	e 6.5117, p	0 < 0.01	ć				
Random effects model	199642	830546379	•		2115.5	[1176.8; 3800.1]	
$ \begin{array}{cccc} \mbox{Heterogeneity:} \ l^2 = 100\%, \ t^2 = 7.3167, \ p < 0.01 & 0 & 50000 & 1e+05 & 150000 & 2e+05 & 250000 \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$							

For the Ab Rahmam 2022 study, the total number of COVID-19 vaccines presented is lower than the reported number because some counts did not specify the type of COVID vaccine taken and therefore could not be included.

FIGURE S10. INCIDENCE OF CARDIAC ARRHYTHMIAS AMONG THOSE RECEIVING THEIR FIRST, SECOND, AND THIRD DOSE OF COVID-19 VACCINE

Study	Events	Total	Case	əs per mi	illion vaccine doses(95%Cl)
dose = first dose			<u>*</u>		
Kaur,2021	4	804		4975.1	[1357.2; 12688.9]
Lai,2022	7	138141		50.7	[20.4; 104.4]
Patone,2022	42740	38615491		1106.8	[1096.3; 1117.3]
Ortiz-Prado,2022	176	6654	2	26450.3	[22728.1; 30594.8]
Farhat,2022	95	989	ý <u> </u>	6056.6	[78410.5; 116148.4]
Abdel-Qader,2022	2430	658428		3690.6	[3545.6; 3840.0]
Basavaraja,2021	2	3814		524.4	[63.5; 1893.0]
Wong,2022	253	2264679		111.7	[98.4; 126.4]
Vanijcharoenkarn,2021	16	20657		774.6	[442.8; 1257.5]
Alghamdi,2021	462	4170	1	10791.	[101420.0; 120711.8]
Alghamdi,2022	59	526	411	2167.3	[86491.2; 142294.5]
Abu-Hammad,2021	1	409	÷	2445.0	[61.9; 13546.7]
Random effects model	46245	41714762	<u>r</u> .	3450.9	[988.2; 11977.6]
			e 🆕		- / -
Heterogeneity: $I^2 = 100\%$, τ^2	= 6.7465, p	0 < 0.01	í ř		
dose = second dose					
Kaur,2021	0	802	E .	0.0	[0.0; 4589.0]
Mansanguan,2022	53	301	17	6079.7	[134766.1; 223902.6]
Lai,2022	12	119664		100.3	[51.8; 175.2]
Patone,2022	44014	32095748	1	1371.3	[1358.6; 1384.2]
Ortiz-Prado,2022	81	6654	1	2173.1	[9678.7; 15107.7]
EI-Shitany,2022	25	442	5	6561.1	[36934.1; 82365.7]
Farhat,2022	85	978	8	36912.1	[70010.5; 106347.1]
Abdel-Qader,2022	1538	374002		4112.3	[3909.7; 4322.6]
Basavaraja,2021	0	3921		0.0	[0.0; 940.4]
Wong,2022	205	1938237		105.8	[91.8; 121.3]
Random effects model	46013	34540749		2262.5	[2205.9; 2320.7]
Heterogeneity: $I^2 = 100\%$, τ^2	= 9.9602, p	o < 0.01			- / -
dose = third dose			• (
El-Shitany 2022	30	442	· 6	37873.3	[46259 0: 95478 0]
Farhat 2022	1	144		6944 4	[175.8; 38083.3]
Chen 2022	78	7382	10	0566.2	[8360 9: 13169 8]
Random effects model	109	7968	r • 1	9064.3	[5775.5: 61051.2]
Rundom cheets mouer	100	1000		5004.5	[51/5.5, 51051.2]
Heterogeneity: $I^2 = 97\%$, $\tau^2 =$	= 0.9344, p	< 0.01			
Random effects model	92367	76263479		3615.4	[1282.4; 10149.1]
Heterogeneity: I^2 = 100%, τ^2	= 7.3707, <i>p</i>	o < 0.01	0 50000 1e+05 150000 2e+05 250000		

Test for subgroup differences (random effects): χ_2^2 = 12.59, df = 2 (p < 0.01)

FIGURE S11. INCIDENCE OF CARDIAC ARRHYTHMIAS AFTER VACCINATION AMONG ADULTS AND CHILDREN

Study	Events	Total					с	ases per mil	llion vaccine doses(95%Cl)
Age = Adult			I						
Kaasenbrood,2016	37	9450	•					3915.3	[2758.2; 5392.8]
Sniadack,2008	89	37901						2348.2	[1886.2; 2888.9]
Haber,2016	5	16000000	4					0.3	[0.1; 0.7]
Ankrah,2013	6	5870						1022.1	[375.2; 2223.4]
Kaur,2021	4	1606						2490.7	[679.0; 6364.7]
Montano,2021	98397	890116274						110.5	[109.9; 111.2]
Almufty,2021	2	1012						1976.3	[239.4; 7120.6]
Abdel-Qader,2022	3968	1032430	•					3843.4	[3724.9; 3964.6]
Cari,2021	7791	266984159						29.2	[28.5; 29.8]
Basavaraja,2021	2	7735						258.6	[31.3; 933.7]
Engler,2015	14	1270	í 🕂					11023.6	[6039.5; 18426.7]
Wong,2022	458	4202916	•					109.0	[99.2; 119.4]
Random effects model	110773	1178400623	l					412.8	[269.7; 631.7]
Heterogeneity: $I^2 = 100\%$, τ^2	= 7.6186, p	0 < 0.01							
Age = Children			l						
Aguirre-Boza,2021	5	4951556	1					1.0	[0.3; 2.4]
Mansanguan,2022	53	301	ļ		+			176079.7	[134766.1; 223902.6]
Lai,2022	19	257805						73.7	[44.4; 115.1]
Tavakoli,2022	18	11042	•					1630.1	[966.4; 2575.1]
Random effects model	95	5220704	ļ					390.7	[9.2; 16394.1]
1 = 1000 (-2)	- 00 4670	n < 0.01							
Heterogeneity. $T = 100\%$, τ	- 20.1679,	p < 0.01	l						
Random effects model	110868	1183621327	•					408.0	[185.6; 896.6]
						-			
Heterogeneity: $I^2 = 100\%$. τ^2	0 50000	1e+05 1	50000 2	e+05	250000				
Test for subgroup differences (random effects): $\chi_1^2 = 0.00$, df = 1 ($p = 0.98$)									